Market Intelligence, Clinical Progress, and High-Purity Reagents for Fibrosis and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CTHRC1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CTHRC1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View CTHRC1 Products |
| Gene Delivery | CTHRC1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and functional migration assays. |
View CTHRC1 Products |
| Benchmark Ab | Anti-CTHRC1 Recombinant Antibody Recombinant positive control for neutralization and binding assays. |
View CTHRC1 Products |
| Validator | CTHRC1 siRNA Set For knockdown verification in functional phenotypic assays. |
View CTHRC1 Products |
| Related Target A | TGFB1 Synergistic driver of myofibroblast activation and tissue fibrosis. |
View TGFB1 Products |
| Related Target B | FAP Marker of cancer-associated fibroblasts (CAFs) co-localizing with CTHRC1. |
View FAP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of Triple Helix | HEK293 mammalian expression system preserves native disulfide bonds and glycosylation patterns. |
| Cross-species ortholog evaluation | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies included in the catalog. |
| False Positives | Sequence-specific siRNA pools included for target-specific knockdown verification. |
Live CTHRC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CTHRC1 therapeutics is intensifying, with major players shifting focus from traditional systemic cytostatics to stromal-targeting monoclonal antibodies and multi-specific constructs. As first-generation therapies targeting the tumor microenvironment reach the clinic, the next wave of R&D is targeting CTHRC1 to suppress cancer-associated fibroblast (CAF) activation and reverse epithelial-mesenchymal transition (EMT) in solid tumors, as well as halt progression in idiopathic pulmonary fibrosis (IPF).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Biotech Innovators, Academic Spin-offs | Solid Tumors (Pancreatic, Gastric), IPF | Neutralization Assay (Need high-purity, natively folded CTHRC1 protein) |
| Bispecific Antibody | Oncology-focused Biopharma | Metastatic Colorectal Cancer | Dual-targeting Validation (Need cross-reactive antigens and stable cell lines) |
| siRNA / RNAi | RNA Therapeutics Specialists | Hypertrophic Scars, Fibrotic Diseases | In Vitro Knockdown Validation (Need sequence-verified siRNA sets) |